The Global Cell Therapy Manufacturing Industry is poised for remarkable growth, fueled by a groundbreaking discovery. According to a recent analysis, the market is expected to reach a staggering US$15,634.67 million by 2033, reflecting a robust Compound Annual Growth Rate (CAGR) of 14.2%. This impressive projection signifies a significant leap from the market’s estimated value of US$4,134.48 million at the end of 2023.
Autologous Cell Therapy Manufacturing Leads Charge with 56.0% Dominance in 2021
Driving this dynamic landscape is autologous cell therapy manufacturing, spearheading an impressive 56.0% market share in 2021. This dominance underscores the pivotal role autologous therapies play in shaping the future of healthcare solutions. As the industry evolves, the prominence of autologous cell therapy manufacturing continues to pave the way for groundbreaking advancements.
Quality Standards Evolution Fuels Advancements in Cell Therapy Manufacturing
The industry’s relentless pursuit of excellence is evident in the evolving quality standards within cell therapy manufacturing processes. This evolution directly translates to enhanced product consistency, reliability, and efficacy. The result is the emergence of sophisticated gene-edited cell-based products, exemplified by the revolutionary chimeric antigen receptor (CAR)-T cells, and groundbreaking tissue engineering products like Holoclar.
Shaping the Future of Healthcare Solutions
As the Global Cell Therapy Manufacturing Industry continues its exponential growth, it solidifies its position as a key player in shaping the future of healthcare solutions. The 14.2% CAGR forecasted from 2023 onwards reflects the industry’s resilience and commitment to innovation. The groundbreaking advancements in autologous cell therapy and the continuous evolution of quality standards affirm the industry’s dedication to providing cutting-edge solutions that redefine healthcare.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-15536
Many academic centers are nowadays investing in the development of such automated devices for point-of-care manufacturing and engagement in decentralized multi-center Clinical Trials. The Global Cell Therapy Manufacturing Industry would thus observe a boom in the next decade. Besides, the introduction of novel therapies licensed by regulatory bodies for targeted therapeutic approaches would further propel the overall growth in the market during the projected period.
Key Takeaways from the Global Cell Therapy Manufacturing Industry Study
- By source, the autologous segment held a global market share of about 0% in 2021.
- Based on indication, the cancer segment held nearly 0% in 2021 in the cell therapy manufacturing market.
- In terms of purpose, the clinical segment accounted for around 0% of the global market share in 2021.
- The injectable route of administration of cell therapies generated a global market share of around 0% in 2021.
- By cell type, the hematopoietic stem cells (HSC) segment held a share of around 0% in the global cell therapy manufacturing market in 2021.
- By end use, the hospital settings category generated a share of around 1% in 2021 in the global cell therapy manufacturing market.
- China held a share of around 2% in 2021 in the East Asia cell therapy manufacturing market.
“Increasing number of research activities by key companies to reduce risks and get ready for a highly productive future are anticipated to drive the market. Besides, they are striving to develop innovative technologies that can assist investigators in automating their processes for gaining success in future,”says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)
Competitive Landscape: Global Cell Therapy Manufacturing Industry
Key players in the cell therapy manufacturing market are focusing on R&D activities to initiate regenerative medicine manufacturing. Moreover, they are promoting commercial manufacturing for their clients by offering novel solutions to cell therapy developers.
For instance,
- In March 2022, Thermo Fisher Scientific presented a new large-volume electroporation system, the purpose of which is to simplify cell therapy development. The company aims to simplify the transition from clinical development to commercial manufacturing among Cell Therapy Developers.
- Charles River Laboratories’ Memphis plant became the first CDMO in North America to manufacture commercial allogeneic cell therapies after receiving European Medicines Agency (EMA) approval in August 2022.
Request Your Customized Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-15536
Get Exclusive Insights on the Global Cell Therapy Manufacturing Industry
Future Market Insights offers a unique perspective and actionable insights on the cell therapy manufacturing market in its latest study, presenting a historical demand assessment of 2012 – 2021 and projections for 2022 – 2032. The Global Cell Therapy Manufacturing Industry is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Global Cell Therapy Manufacturing Industry Key Players:
- Merck KGaA
- Avantor, Inc.
- Cell Therapies Pty Ltd
- Thermo Fisher Scientific
- Charles River Laboratories
- Catalent, Inc
- Bio-Techne
- Cytiva
- Lonza
- The Discovery Labs
- BIOCENTRIQ
- FUJIFILM Diosynth Biotechnologies
- Novartis AG
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- WuXi AppTec.
- OXGENE
- Pharmaron
- Aldevron
- FLODESIGN SONICS
- Exothera
Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/15536
Key Segments Covered in the Global Cell Therapy Manufacturing Industry
By Source:
- Autologous
- Allogenic
By Indication:
- HIV
- Autoimmune Disorders
- Immune Deficiencies
- Cancer
- Neurological Disorders
By Manufacturing Purpose:
- Clinical
- Commercial
- Pre-clinical
By Route of Administration:
- Topical
- Injectable
- Infusion
- Implantable Bio-Scaffold
By Cell Type:
- Hematopoietic (Blood-Forming) Stem Cells (HSC)
- Skeletal Muscle Stem Cells
- Mesenchymal Stem Cells
- Lymphocytes
- Dendritic Cells
- Pancreatic Islet Cells
- CAR-T Cells
By End User:
- Hospital Settings
- Intensive Outpatient Treatment Centers
- Academic and Research Institutes
- Specialty Clinics
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube